Search Results - "Davis, Vicki G"

The Banff Working Group Classification of Definitive Polyomavirus Nephropathy: Morphologic Definitions and Clinical Correlations by Nickeleit, Volker, Singh, Harsharan K, Randhawa, Parmjeet, Drachenberg, Cinthia B, Bhatnagar, Ramneesh, Bracamonte, Erika, Chang, Anthony, Chon, W James, Dadhania, Darshana, Davis, Vicki G, Hopfer, Helmut, Mihatsch, Michael J, Papadimitriou, John C, Schaub, Stefan, Stokes, Michael B, Tungekar, Mohammad F, Seshan, Surya V

“…Polyomavirus nephropathy (PVN) is a common viral infection of renal allografts, with biopsy-proven incidence of approximately 5%. A generally accepted…”
Get full text

Placebo Response and Practice Effects in Schizophrenia Cognition Trials by Keefe, Richard S E, Davis, Vicki G, Harvey, Philip D, Atkins, Alexandra S, Haig, George M, Hagino, Owen, Marder, Stephen, Hilt, Dana C, Umbricht, Daniel

“…Patients' previous experience with performance-based cognitive tests in clinical trials for cognitive impairment associated with schizophrenia can create…”
Get more information

The Urinary Polyomavirus-Haufen Test: A Highly Predictive Non-Invasive Biomarker to Distinguish "Presumptive" from "Definitive" Polyomavirus Nephropathy: How to Use It-When to Use It-How Does It Compare to PCR Based Assays? by Nickeleit, Volker, Davis, Vicki G, Thompson, Bawana, Singh, Harsharan K

“…"Definitive" biopsy proven polyomavirus nephropathy (PyVN), usually caused by BK polyomavirus (BKPyV), remains a significant infection of kidney transplants…”
Get full text

Increasing Incidence of Inadequate Kidney Biopsy Samples Over Time: A 16-Year Retrospective Analysis From a Large National Renal Biopsy Laboratory by Nissen, Caleb J., Moreno, Vanessa, Davis, Vicki G., Walker, Patrick D.

“…Renal biopsy remains an essential tool for the diagnosis and treatment of patients with medical kidney disease. Recently, there has been a perceived change in…”
Get full text

Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale by Keefe, Richard S.E, Davis, Vicki G, Spagnola, Nathan B, Hilt, Dana, Dgetluck, Nancy, Ruse, Stacy, Patterson, Thomas D, Narasimhan, Meera, Harvey, Philip D

“…Abstract Cognitive functioning can be assessed with performance-based assessments such as neuropsychological tests and with interview-based assessments. Both…”
Get full text

Virtual reality functional capacity assessment in schizophrenia: Preliminary data regarding feasibility and correlations with cognitive and functional capacity performance by Ruse, Stacy A, Harvey, Philip D, Davis, Vicki G, Atkins, Alexandra S, Fox, Kolleen H, Keefe, Richard S.E

“…Abstract Introduction Assessment of functional capacity is an intrinsic part of determining the functional relevance of response to treatment of cognitive…”
Get full text

The 2018 Banff Working Group classification of definitive polyomavirus nephropathy: A multicenter validation study in the modern era by Nickeleit, Volker, Singh, Harsharan K., Dadhania, Darshana, Cornea, Virgilius, El‐Husseini, Amr, Castellanos, Ana, Davis, Vicki G., Waid, Thomas, Seshan, Surya V.

“…Polyomavirus nephropathy (PVN) remained inadequately classified until 2018 when the Banff Working Group published a new 3‐tier morphologic classification…”
Get full text

Validation of a Computerized test of Functional Capacity by Keefe, Richard S.E, Davis, Vicki G, Atkins, Alexandra S, Vaughan, Adam, Patterson, Tom, Narasimhan, Meera, Harvey, Philip D

“…Abstract Regulatory guidance for schizophrenia cognition clinical trials requires that the assessment of cognitive change is accompanied by a functionally…”
Get full text

Classifying Polyomavirus Nephropathy: The "Banff" Initiative by Nickeleit, Volker, Singh, H K, Davis, Vicki G, Seshan, Surya V

Get full text

Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients by Georgiades, Anastasia, Davis, Vicki G, Atkins, Alexandra S, Khan, Anzalee, Walker, Trina W, Loebel, Antony, Haig, George, Hilt, Dana C, Dunayevich, Eduardo, Umbricht, Daniel, Sand, Michael, Keefe, Richard S.E

“…Abstract The MATRICS Consensus Cognitive Battery (MCCB) was developed to assess cognitive treatment effects in schizophrenia clinical trials, and is considered…”
Get full text

Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study by Daumit, Gail L, Goff, Donald C, Meyer, Jonathan M, Davis, Vicki G, Nasrallah, Henry A, McEvoy, Joseph P, Rosenheck, Robert, Davis, Sonia M, Hsiao, John K, Stroup, T. Scott, Lieberman, Jeffrey A

“…Abstract Objective Persons with schizophrenia die earlier than the general population, in large part due to cardiovascular disease. The study objective was to…”
Get full text

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1 by Meyer, Jonathan M, Davis, Vicki G, Goff, Donald C, McEvoy, Joseph P, Nasrallah, Henry A, Davis, Sonia M, Rosenheck, Robert A, Daumit, Gail L, Hsiao, John, Swartz, Marvin S, Stroup, T. Scott, Lieberman, Jeffrey A

“…Abstract Background The metabolic syndrome (MS) is associated with increased risk for diabetes mellitus and coronary heart disease, and is highly prevalent…”
Get full text

Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study by Meyer, Jonathan M, McEvoy, Joseph P, Davis, Vicki G, Goff, Donald C, Nasrallah, Henry A, Davis, Sonia M, Hsiao, John K, Swartz, Marvin S, Stroup, T. Scott, Lieberman, Jeffrey A

“…Background C-reactive protein (CRP), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin are systemic…”
Get full text

The Brief Assessment of Cognition In Affective Disorders (BAC-A):Performance of patients with bipolar depression and healthy controls by Keefe, Richard S.E, Fox, Kolleen H, Davis, Vicki G, Kennel, Courtney, Walker, Trina M, Burdick, Katherine E, Harvey, Philip D

“…Abstract Background Cognitive deficits in bipolar disorder are significant enough to impact everyday functioning. A key question for treatments aimed at…”
Get full text

Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia by Caroff, Stanley N, Davis, Vicki G, Miller, Del D, Davis, Sonia M, Rosenheck, Robert A, McEvoy, Joseph P, Campbell, E Cabrina, Saltz, Bruce L, Riggio, Silvana, Chakos, Miranda H, Swartz, Marvin S, Keefe, Richard S E, Stroup, T Scott, Lieberman, Jeffrey A

“…We compared the response to antipsychotic treatment between patients with and without tardive dyskinesia (TD) and examined the course of TD. This analysis…”
Get full text

Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1 by Meyer, Jonathan M, Davis, Vicki G, McEvoy, Joseph P, Goff, Donald C, Nasrallah, Henry A, Davis, Sonia M, Daumit, Gail L, Hsiao, John, Swartz, Marvin S, Stroup, T. Scott, Lieberman, Jeffrey A

“…Abstract Background Recent literature documents a stronger association between nonfasting triglycerides (TG) and cardiovascular risk compared to fasting TG…”
Get full text

Circadian rhythms in cognitive functioning among patients with schizophrenia: Impact on signal detection in clinical trials of potential pro-cognitive therapies by Hufford, Michael R, Davis, Vicki G, Hilt, Dana, Dgetluck, Nancy, Geffen, Yona, Loebel, Antony, Haig, George, Santarelli, Luca, Keefe, Richard S.E

“…Abstract Objective Cognition is affected by circadian rhythms over the course of a day. Circadian rhythms in cognitive functioning are driven by a variety of…”
Get full text

Development of a virtual reality assessment of everyday living skills by Ruse, Stacy A, Davis, Vicki G, Atkins, Alexandra S, Krishnan, K Ranga R, Fox, Kolleen H, Harvey, Philip D, Keefe, Richard S E

“…Cognitive impairments affect the majority of patients with schizophrenia and these impairments predict poor long term psychosocial outcomes.  Treatment studies…”
Get full text

Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial by Rosenheck, Robert A, Davis, Vicki G, Davis, Sonia M, Stroup, Scott, McEvoy, Joseph, Swartz, Marvin, Lieberman, Jeffrey

“…Abstract Background One of the major challenges in the design of double-blind flexible-dosing clinical trials comparing active drugs is the selection of dosing…”
Get full text

Previous angina alters in-hospital outcome in TIMI 4 : a clinical correlate to preconditioning ? by KLONER, R. A, SHOOK, T, MCCABE, C. H, BRAUNWALD, E, PRZYKLENK, K, DAVIS, V. G, JUNIO, L, MATTHEWS, R. V, BURSTEIN, S, GIBSON, C. M, POOLE, W. K, CANNON, C. P

“…Ischemic preconditioning has been shown to reduce myocardial infarct size in experimental models, but its role in patients remains unclear. Angina before…”
Get full text